Synergistic Antiviral Systems Integrating Pharmaceutical Compositions with AI, IoT, and Blockchain Technologies

The inventive concept integrates pharmaceutical compositions comprising substituted nucleotides and nucleosides with advanced technologies such as AI, IoT, and blockchain to create a powerful system for treating viral infections, enhancing treatment efficacy, and ensuring secure and transparent tracking of pharmaceutical compositions.

The original patent disclosed pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections. However, the patent did not address the limitations of tracking treatment efficacy, ensuring secure distribution, and optimizing nucleoside analog delivery. The new inventive concept addresses these limitations by integrating the patented pharmaceutical compositions with AI, IoT, and blockchain technologies.

The inventive concept combines the pharmaceutical compositions of the original patent with AI-powered diagnostic tools for identifying viral infections, machine learning algorithms for optimizing nucleoside analog delivery, and blockchain-based tracking systems for monitoring treatment efficacy. The system utilizes lipid-based conjugates and nanocarrier systems for targeted delivery to infected cells. Additionally, the system incorporates a decentralized ledger for recording treatment outcomes and a smart contract for automating reward distribution based on efficacy metrics.

The new inventive concept introduces a synergistic combination of pharmaceutical compositions with AI, IoT, and blockchain technologies, which is novel and non-obvious compared to the original patent. The integration of these technologies enables a more powerful system for treating viral infections, enhancing treatment efficacy, and ensuring secure and transparent tracking of pharmaceutical compositions.

Alternative embodiments of the inventive concept may include the use of different AI algorithms, IoT devices, or blockchain platforms. Additionally, the system could be adapted for use with other types of infections or diseases, or for use in veterinary medicine.

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of antiviral treatment and disease management. The system's ability to enhance treatment efficacy, ensure secure and transparent tracking, and optimize nucleoside analog delivery makes it an attractive solution for pharmaceutical companies, healthcare providers, and patients.